Lu Huang
Director/Board Member at Arctic Vision (Shanghai) Biotechnology Co., Ltd.
Network origin in Lu Huang first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Arctic Vision (Shanghai) Biotechnology Co., Ltd.
 Arctic Vision (Shanghai) Biotechnology Co., Ltd. Pharmaceuticals: MajorHealth Technology Arctic Vision (Shanghai) Biotechnology Co., Ltd. is a Chinese Shanghai-based ophthalmic biotech company that focuses on developing innovative therapies to address unmet clinical needs and benefit ophthalmic patients. The company is led by an elite team of ophthalmic industry veterans with substantial experience in R&D and commercialization of eye care products. Arctic Vision has top-tier biotech venture capital investors with a broad network in both the U.S. and European ophthalmic markets, and an unprecedented track record in company incubation. The company was founded by Hai Di Hu, who has been the CEO since incorporation.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Lu Huang via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Loyal Valley Capital Co. Ltd.
 Loyal Valley Capital Co. Ltd. Investment ManagersFinance Loyal Valley Capital Co. Ltd (LVC) is an independent private equity firm founded by Li Jun Lin in 2015. The firm is headquartered in Shanghai, China. | Investment Managers | Private Equity Investor | |
Regor Therapeutics Group
 Regor Therapeutics Group Miscellaneous Commercial ServicesCommercial Services Regor Therapeutics Group is a biotech company founded in 2018 by a team of scientists with expertise in drug discovery and development. The company is based in Boston, MA and has subsidiaries in China. Regor Therapeutics Group utilizes its industry-leading core strength in Rcard™ to accelerate the discovery of innovative therapeutic agents. The company has completed 8 PCCs in-house, with 5 INDs filed, and has a pipeline of leading assets in metabolism, oncology, and auto-immunity. The company's two leading assets are RGT-075, an orally bioavailable small molecule GLP1R full agonist with potential for obesity and beyond, and RGT-419B, a unique CDK4+ inhibitor showing outstanding single agent responses in refractory ER+/HER2- breast cancer patients. The company was founded in 2018, and the CEO is Xiayang Qiu. | Miscellaneous Commercial Services | Director/Board Member | |
| Fudan University | College/University | Graduate Degree | |
| Renmin University of China | College/University | Undergraduate Degree |
Statistics
International
| China | 4 |
| United States | 2 |
Sectoral
| Consumer Services | 3 |
| Finance | 2 |
| Commercial Services | 2 |
Operational
| Director/Board Member | 3 |
| Private Equity Investor | 1 |
| Graduate Degree | 1 |
| Undergraduate Degree | 1 |
| Chairman | 1 |
Most connected contacts
| Insiders | |
|---|---|
| Ling Xu | 5 |
| Jing Qian | 1 |
| Hai Di Hu | 1 |
- Stock Market
- Insiders
- Lu Huang
- Company connections
